Ascletis Pharma Inc.
ASCLFOTCHealthcare● Active
$1.35
+$0.03(+2.27%)
Market Cap$1.4B
P/E Ratio—
52W High$2.5
52W Low$0.9325
Ascletis Pharma Inc. (ASCLF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ASCLF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.98M | $1.28M | $56.60M | $54.09M | $76.88M |
| Cost of Revenue | $18.62M | $0.55M | $30.61M | $78.78M | $37.70M |
| Gross Profit | ($16.65M) | $0.73M | $25.99M | ($24.69M) | $39.17M |
| Gross Margin %(computed) | -842.70% | 57.29% | 45.92% | -45.65% | 50.96% |
| Operating Expenses | |||||
| R&D Expenses | $387.75M | $302.39M | $216.78M | $267.10M | $213.32M |
| G&A Expenses | $0.00M | $101.74M | $62.58M | $15.43M | $16.49M |
| Total Operating Expenses | $454.63M | $296.15M | $326.20M | $319.29M | $264.14M |
| Operating Income | ($471.27M) | ($295.42M) | ($300.21M) | ($343.98M) | ($224.97M) |
| Operating Margin %(computed) | — | — | -530.44% | -635.94% | -292.63% |
| Interest Income | $63.98M | $91.99M | $99.28M | $44.16M | $22.51M |
| Interest Expense | $0.16M | $0.00M | $0.14M | $0.16M | $0.13M |
| Income Before Tax | ($350.10M) | ($300.94M) | ($144.72M) | ($314.84M) | ($199.02M) |
| Income Tax Expense | ($0.49M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($350.59M) | ($300.94M) | ($144.72M) | ($314.84M) | ($199.02M) |
| Net Margin %(computed) | — | — | -255.70% | -582.07% | -258.88% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.36 | $-0.30 | $-0.13 | $-0.29 | $-0.18 |
| Wtd Avg Shares | 972.51M | 1001.59M | 1074.11M | 1087.03M | 1097.61M |
| EBITDA | ($454.11M) | ($390.45M) | ($126.09M) | ($284.50M) | ($169.35M) |
| EBITDA Margin %(computed) | — | — | -222.79% | -525.97% | -220.29% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CNY · M
Explore more Ascletis Pharma Inc. data
About Ascletis Pharma Inc. (ASCLF) Income Statement
Ascletis Pharma Inc. (ASCLF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ASCLF reported revenue of $0.00B, gross profit of ($0.02B) (gross margin -842.70%), and net income of ($0.35B) — a net profit margin of -17745.60%.
Frequently asked questions
ASCLF · 4 questionsAscletis Pharma Inc. (ASCLF) reported revenue of $0.00B for 2025, up 54.0% year-over-year.
ASCLF revenueASCLF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09